Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation support: a consequence of vaping

Caroline M. Patterson, Kamen Valchanov, Allanah Barker, Martin Goddard, Huina Yang, Angus G. Butchart
ERJ Open Research 2020 6: 00013-2020; DOI: 10.1183/23120541.00013-2020
Caroline M. Patterson
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamen Valchanov
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allanah Barker
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Goddard
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huina Yang
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angus G. Butchart
Royal Papworth Hospital NHS Foundation Trust, Cambridge , UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: angusbutchart@nhs.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In the past decade, vaping has become more prevalent globally. Since mid-2019, reports have linked the use of vaping devices to lung injury (EVALI). This is the first reported adult case outside the USA to require ECMO for a severe vaping complication. https://bit.ly/39hf2ZY

To the Editor:

Since the emergence of electronic cigarette products on the retail market just over a decade ago, there has been an exponential rise in their use, particularly amongst young adults [1] and the global market is now estimated by Euromonitor International to be worth $19.3 billion, up from $6.9 billion 5 years ago [2]. Despite being marketed as a safer alternative to traditional cigarettes, “vaping” generates aerosols containing a heterogenous mix of potentially harmful substances and pulmonary disease related to vaping has been identified in recent case clusters [3–5].

We present the case of a previously fit and well man in his 40s who attended the emergency department with a 10-day history of coryzal symptoms, pleuritic chest pain and worsening shortness of breath. His only medical history was an appendicectomy. He reported a 20-pack-year cigarette smoking history, cannabis use in the distant past and occasional binge drinking of alcohol. He had ceased smoking cigarettes 6 weeks previously and had commenced the regular use of a peppermint-flavoured vaping device as an aid to ongoing smoking cessation. His vaping device contained 18 mg·mL−1 nicotine without tetrahydrocannabinol (THC).

On arrival to hospital he was normothermic, hypoxic and tachycardic. The emergency department physicians noted halitosis. His initial chest radiograph demonstrated a large bulla in the right lower zone, and opacification of the right lower zone and lingula. Within hours of presentation, he required intubation and mechanical ventilation, and he continued to deteriorate over subsequent hours, developing severe acute respiratory distress syndrome (ARDS) necessitating venovenous extracorporeal membrane oxygenation (ECMO).

At the time of instituting ECMO, <24 h after hospital presentation, the patient was in extremis, with an arterial oxygen tension of 6.1 kPa, on maximal ventilatory support with 100% inspired oxygen, and profoundly acidaemic, with a pH 6.99, arterial carbon dioxide of 11.1 kPa and a lactataemia of 7.8 mmol·L−1. There was significant cardiovascular instability with a heart rate of 120 beat·min−1 and mean arterial blood pressure of 55 mmHg on noradrenaline 0.8 μg·kg−1·min−1 and adrenaline 0.2 μg·kg−1·min−1.

Computed tomography (figure 1) demonstrated a destructive process and features consistent with ARDS. There was widespread patchy bilateral lung consolidation, a right sided bronchopleural fistula with a collapsed right lower lobe and associated right hydropneumothorax. Background bullous disease and emphysema were noted. There were no enlarged thoracic lymph nodes.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Coronal reconstructions of thin-slice axial computed tomography of the chest.

His initial white cell count and C-reactive protein measured 10.6×109 L−1 and 272 mg·L−1 respectively. Other than Candida albicans in his sputum at admission, there were no positive cultures from sputum, blood or bronchoalveolar lavage (BAL), and PCR assays for bacterial, fungal and viral pathogens were negative. An HIV test was negative and an autoimmune screen was also negative. His BAL cytology demonstrated a predominance of lipid-laden alveolar macrophages without significant neutrophilia or eosinophilia and there were no features to suggest malignancy.

Based on the Centers for Disease Control and Prevention (CDC) Case Definition Case Definitions [6], this patient met the criteria for a “confirmed” diagnosis of vaping-associated lung injury (EVALI). Although his radiology highlighted a degree of pre-existing structural lung disease, in-keeping with his history of cannabis and cigarette exposure, his acute decline occurred within 90 days of vape exposure and in the absence of confirmed pulmonary infection or another plausible diagnosis. EVALI is associated with a range of pneumonitis patterns on imaging; however, dependent consolidation and diffuse ground-glass opacification, as seen in this patient, are well recognised [7]. The identification of foamy macrophages in his BAL is also believed by some clinicians to support the diagnosis [8–10].

Globally, there is an increasing recognition of the potential hazards of vaping, with case reports emerging in the medical literature and popular press [3, 4, 5, 11]. In the USA, the CDC have identified 2807 cases of lung injury requiring hospitalisation and 68 deaths associated with the use of vaping products (data as of 18 February 2020). Two thirds of hospitalised patients are male, with a median age of 24 years [12]. The incidence of EVALI outside the USA has yet to be defined. This is the first reported adult case of EVALI outside the USA to require ECMO support.

The aetiology and mechanism of EVALI remain unclear but it is postulated that exposure to inhaled toxic substances may lead to an airway-centred chemical pneumonitis [8, 13, 14]. The high percentage of patients with EVALI who report the use of THC-containing products (∼80%) warrants closer evaluation [11, 15]. Vitamin E acetate and pulegone (used in mint and menthol flavouring) are also emerging as potentially significant toxicants [16, 17].

Since May 2017, UK regulations have restricted e-liquids to a nicotine strength of ≤20 mg·mL−1 and specific ingredients, including THC and vitamin E acetate, are not permitted. Similar restrictions exist across Europe. It is uncertain whether these regulations have contributed to the lower frequency of EVALI cases reported in the UK and Europe compared to the USA.

In summary, the patient we present developed a life-threatening acute lung injury following exposure to a vaping device in the UK. He ultimately survived this acute illness and was repatriated to his referring hospital after the discontinuation of ECMO support. This case highlights that EVALI is not an exclusively North American phenomenon and while the risks may be ameliorated by UK and European legislation to reduce inhaled toxicant exposure, there is an ongoing hazard of life-threatening lung injury associated with the use of these devices.

Footnotes

  • Conflict of interest: C.M. Patterson has nothing to disclose.

  • Conflict of interest: K. Valchanov has nothing to disclose.

  • Conflict of interest: A. Barker has nothing to disclose.

  • Conflict of interest: M. Goddard has nothing to disclose.

  • Conflict of interest: H. Yang has nothing to disclose.

  • Conflict of interest: A.G. Butchart has nothing to disclose.

  • Received January 15, 2020.
  • Accepted March 17, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Mirbolouk M,
    2. Charkhchi P,
    3. Kianoush S, et al.
    Prevalence and distribution of e-cigarette use among U.S. adults: behavioral risk factor surveillance system, 2016. Ann Intern Med 2018; 169: 429–438. doi:10.7326/M17-3440
    OpenUrl
  2. ↵
    1. Jones L
    . Vaping: how popular are e-cigarettes? www.bbc.co.uk/news/business-44295336 Date last accessed: 1 October 2019. Date last updated: 15 September 2019.
  3. ↵
    1. Layden J,
    2. Ghinai I,
    3. Pray I, et al.
    Pulmonary illness related to e-cigarette use in Illinois and Wisconsin – final report. N Engl J Med 2020; 382: 903–916. doi:10.1056/NEJMoa1911614
    OpenUrl
  4. ↵
    1. Hswen Y,
    2. Brownstein J
    . Real-time digital surveillance of vaping-induced pulmonary disease. N Engl J Med 2019; 381: 1778–1780. doi:10.1056/NEJMc1912818
    OpenUrl
  5. ↵
    1. Kalininskiy A,
    2. Bach C,
    3. Nacca N, et al.
    E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med 2019; 7: 1017–1026. doi:10.1016/S2213-2600(19)30415-1
    OpenUrl
  6. ↵
    Centers for Disease Control and Prevention. 2019 lung injury surveillance primary case definitions. www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdf Date last accessed: 1 October 2019. Date last updated: 18 September 2019.
  7. ↵
    1. Henry T,
    2. Kanne J,
    3. Kligermann S
    . Imaging of vaping-associated lung disease. N Engl J Med 2019; 381: 1486–1487. doi:10.1056/NEJMc1911995
    OpenUrl
  8. ↵
    1. Butt Y,
    2. Smith M,
    3. Tazelaar H, et al.
    Pathology of vaping-associated lung injury. N Engl J Med 2019; 381: 1780–1781. doi:10.1056/NEJMc1913069
    OpenUrl
    1. Maddock S,
    2. Cirulis M,
    3. Callahan S, et al.
    Pulmonary lipid-laden macrophages and vaping. N Engl J Med 2019; 381: 1488–1489. doi:10.1056/NEJMc1912038
    OpenUrlCrossRefPubMed
  9. ↵
    1. Pambuccian SE
    . Testing for lipid-laden macrophages in bronchoalveolar lavage fluid to diagnose vaping-associated pulmonary injury. Are we there yet? J Am Soc Cytopathol 2020; 9: 1–8. doi:10.1016/j.jasc.2019.10.002
    OpenUrl
  10. ↵
    1. Schier J,
    2. Meiman J,
    3. Layden J, et al.
    Severe pulmonary disease associated with electronic-cigarette–product use — interim guidance. MMWR Morb Mortal Wkly Rep 2019; 68: 787–790. doi:10.15585/mmwr.mm6836e2
    OpenUrl
  11. ↵
    Centers for Disease Control and Prevention. Latest information. www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#latest-information Date last accessed: March 10, 2020.
  12. ↵
    1. Lee M,
    2. LeBouf R,
    3. Son Y, et al.
    Nicotine, aerosol particles, carbonyls and volatile organic compounds in tobacco- and menthol-flavored e-cigarettes. Environ Health 2017; 16: 42. doi:10.1186/s12940-017-0249-x
    OpenUrlCrossRef
  13. ↵
    1. Lee M,
    2. Allen J,
    3. Christiani D
    . Endotoxin and (1→3)-β-d-glucan contamination in electronic cigarette products sold in the United States. Environ Health Perspect 2019; 127: 47008. doi:10.1289/EHP3469
    OpenUrl
  14. ↵
    1. He T,
    2. Oks M,
    3. Esposito M, et al.
    “Tree-in-bloom”: severe acute lung injury induced by vaping cannabis oil. Ann Am Thorac Soc 2017; 14: 468–470. doi:10.1513/AnnalsATS.201612-974LE
    OpenUrl
  15. ↵
    1. Blount B,
    2. Karwowski M,
    3. Shields P, et al.
    Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med 2020; 382: 697–705. doi:10.1056/NEJMoa1916433
    OpenUrlCrossRefPubMed
  16. ↵
    1. Jabba S,
    2. Jordt S
    . Risk analysis for the carcinogen pulegone in mint- and menthol-flavored e-cigarettes and smokeless tobacco products. JAMA Intern Med 2019; 179: 1721–1723. doi:10.1001/jamainternmed.2019.3649
    OpenUrl
PreviousNext
Back to top
Vol 6 Issue 2 Table of Contents
ERJ Open Research: 6 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation support: a consequence of vaping
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation support: a consequence of vaping
Caroline M. Patterson, Kamen Valchanov, Allanah Barker, Martin Goddard, Huina Yang, Angus G. Butchart
ERJ Open Research Apr 2020, 6 (2) 00013-2020; DOI: 10.1183/23120541.00013-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation support: a consequence of vaping
Caroline M. Patterson, Kamen Valchanov, Allanah Barker, Martin Goddard, Huina Yang, Angus G. Butchart
ERJ Open Research Apr 2020, 6 (2) 00013-2020; DOI: 10.1183/23120541.00013-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Acute lung injury and critical care
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Procoagulant microparticles and COVID-19
  • Cancer referral and interventional pulmonology during COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society